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Abstract 
Degree project, Programme in Medicine, Do new routines decrease complications after 
treatment of hydrocephalus in children?, Thomas Buske, 2017, the Sahlgrenska Academy, 
University of Gothenburg, Gothenburg, Sweden 
BACKGROUND: A study from 2010 showed that hydrocephalic children undergoing shunt 
surgery or endoscopic third ventriculostomy (ETV) in 2001-2005 at Sahlgrenska University 
Hospital suffered a high rate of failure of treatment, especially due to infection. Other studies 
have reported a significant decrease in infection after implementing a shunt protocol, 
therefore we introduced specific routines in 2012 for ETV/shunt surgery. AIM: This study 
aimed to evaluate the effect of the new protocol on shunt and ETV failure rate. Another aim 
was to identify risk factors for failure of treatment and failure of treatment due to infection. 
METHODS: A search in patient charts was done to include 59 children subject to their first 
shunt/ETV surgery in 2012-2016. Patients were followed until reaching failure of the 
hydrocephalus treatment or until 1st Jan 2017. Statistical analysis was used to compare failure 
rate of the patient population of this study to the population of 2001-2005. Risk factor 
analysis was carried out through Cox regression. RESULTS: Total failure in shunts decreased 
from 58% to 36% (p=0.019). Failure due to infection in shunts decreased from 17% to 9% 
(p=0.180). In shunts, Cox regression did not prove any factors to increase risk of failure of 
treatment, or risk of failure due to infection. CONCLUSIONS: This study suggest that 
implementation of a shunt protocol is an effective way to reduce failure of treatment.  
KEYWORDS: children, failure, hydrocephalus, infection, protocol 
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Background 
Hydrocephalus is a condition where cerebrospinal fluid (CSF) excessively accumulates in the 
ventricles of the brain. This leads to a buildup in pressure and an expansion of the ventricles, 
potentially harming the brain tissue and causing impairments of function. Both children and 
adults are subject to getting the disorder, though more common in the former, where it is 
estimated to occur in 0.8 per 1000 live births [1]. Pediatric hydrocephalus can be either 
congenital or acquired and has several different causes, all of them leading to an imbalance 
between the production of CSF and the absorption into the blood stream. Common etiologies 
are tumor, intraventricular hemorrhage (IVH), aqueductal stenosis (AS), CNS infection, 
myelomeningocele and cysts. The treatment of hydrocephalus consists of one of the two 
possible surgical procedures, either the insertion of a shunt or the performance of an 
endoscopic third ventriculostomy (ETV) [2]. Shunt insertion means diverting CSF from the 
brain’s ventricles to some other part of the body, either to the peritoneal cavity with a 
ventriculoperitoneal shunt (VPS) or to the atrium of the heart with a ventriculoatrial shunt 
(VAS). ETV means creating an opening in the floor of the third ventricle, between the 
ventricle and the subarachnoid cisterns, often to bypass an obstruction of some sort. These 
two ways to manage hydrocephalus are both associated with a high rate of complication 
resulting in the patient requiring new surgery and thereby the failure of the primary treatment 
[3]. The complications leading up to failure of the treatment are slightly different for shunts 
and ETVs, however both can suffer from infections involving the operation wound or the 
CNS. In shunts, complication of mechanical dysfunction can occur, caused by an obstruction 
or overdrainage/underdrainage. In ETVs, complication of insufficient function can occur, due 
to closure of the stoma or insufficient absorption of CSF [4]. 
In 2010, our team published a study regarding children undergoing surgical treatment for 
hydrocephalus in our facilities between 2001-2005. Those patients suffered a relatively high 
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rate of failure, especially due to infection [5]. Other studies had reported a significant 
decrease in infection after implementing a shunt protocol [6, 7]. Therefore in 2012 a protocol 
with specific routines was introduced for shunt and ETV surgery in our facilities, intending to 
decrease infections, thereby decreasing total failure of treatment. 
This study looked at a population of hydrocephalic children in south-western Sweden in 2012-
2016 to investigate the rate of failure of treatment for shunts and ETVs. Results were 
compared to our team’s study of 2010, i.e. prior to protocol introduction. 
Aim 
The aim of this study was to evaluate the effect of the new protocol on shunt and ETV failure 
rate. Failure of treatment due to infection was hypothesized to decrease after protocol 
implementation while the failures due to mechanical dysfunction or insufficient function were 
expected to remain unaltered. Another aim was to identify risk factors for failure of treatment 
and failure of treatment due to infection. 
Material and Methods 
This retrospective study was conducted in Sahlgrenska University Hospital, Gothenburg, 
using the hospital’s electronic patient charts for surgeries where all operations are logged. 
This hospital takes care of all shunt insertions and ETVs in south-western Sweden, a general 
population of about 2 million people. A broad search was done for surgeries performed 
between 2012 and 2016 using the procedure codes for VPS insertion (AAF05), VAS insertion 
(AAF15) and ETV performance (AAF00). The found patients were investigated to exclude 
the ones having received any of the aforementioned procedures before 2012, i.e. before the 
implementation of the protocol. Thereby the only patients included were the ones who 
underwent their first shunt or ETV surgery in 2012 to 2016. Only children aged 0-18 years at 
the time of first procedure were included. The implemented surgery protocol included rules 
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concerning personnel passing in/out of the operation room, more strict use of prophylactic 
antibiotics, surgery staff wearing head cap, surgeon using double gloves, etc. (fully specified 
in appendix 1.). The included patients were investigated for data collection regarding gender, 
age, etiology of hydrocephalus (tumor, malformation, IVH, aqueductal stenosis, CNS 
infection, myelomeningocele, cyst, other), total time of follow up until 1st Jan 2017 and if 
death occurred during study. Surgical data for the primary surgery was collected for type of 
procedure (shunt or ETV), if shunt was antibiotic-impregnated, time of day of surgery 
(morning = 8 am-12 noon, afternoon = 12 noon-6 pm, evening = 6 pm-10 pm, night = 10 pm-
8 am), duration of surgery, emergency procedure (surgery within 24 h of presentation of 
clinical symptoms), department where surgery was performed (department of pediatric 
surgery or department of neurosurgery), any concomitant procedure performed during surgery 
and type of shunt valve used; Codman (Johnson and Johnson, New Brunswick, New Jersey, 
USA), Delta (Medtronic, Fridley, Minnesota, USA) or Strata (also Medtronic). CSF leakage 
occurring after surgery was noted. If the primary surgery was performed within a year from 
the patient’s birth date it was also noted if the patient was born preterm (<35 6/7 weeks of 
gestation). 
Patients were followed until reaching the defined endpoint of this study, being the failure of 
the hydrocephalus treatment. This meaning that the primary surgery of shunt insertion or ETV 
surgery required reoperation because of mechanical dysfunction, insufficient function or 
infection of either CNS or operation wound. The reoperation either consisted of shunt 
revision, removal of the shunt, shunt insertion or ETV. Patients experiencing failure were 
collected for data including time until failure from primary surgery, reason of failure 
(mechanical dysfunction, insufficient function or infection of operation wound/CNS), location 
of obstruction causing mechanical dysfunction of a shunt (ventricle catheter, shunt valve, 
distal catheter, unknown). The treatment failures were evaluated and graded based on their 
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severity; minor (residual symptoms resolving in less than a week), medium (residual 
symptoms resolving in less than three months), serious (residual symptoms for more than 3 
months, with mild sequelae), catastrophic (persistent residual symptoms and serious sequelae 
or death). 
Patients that did not experience a failure of treatment were followed until 1st January 2017, 
allowing a follow up period of at least 1 year after the primary surgical procedure. 
Statistical methods 
Descriptive statistics were computed using either Microsoft Excel 2013 or SPSS version 24 
(IBM, Armonk, New York, USA). To compare data regarding failure, patient data and data 
concerning surgery, statistical tests were executed in SPSS version 24. The used methods 
were Student’s t-test, Welch’s t-test, Mann-Whitney U test, Pearson’s chi-squared test and 
Fisher’s exact test, where the choice of test depended on the type of analyzed data, 
distribution of the data and the sample size. Comparisons were made to our team’s previous 
study covering surgeries in 2001-2005. Kaplan-Meier survival analysis of different treatments 
was carried out in SPSS. Risk factors for failure of treatment were investigated in SPSS by 
constructing several univariate Cox regression models. A separate univariate Cox regression 
model for failure due to infection was also fitted. 95% CI and p-value<0.05 was considered 
statistically significant. 
Ethics 
Since patient data, although coded, was used and analyzed without seeking patient consent, an 
ethical permit was obtained from the regional ethical board of Gothenburg (appendix 2.). 
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Results 
Fifty-nine patients were included in this study, 12 with an ETV and 47 with a shunt. The 
group of 47 shunts included 44 VPSs and 4 VASs. Of the 59 patients, 24 (41%) were female 
and 35 (59%) were men. The median age at surgery was 0.4 and 6.9 years for the population 
of shunt and of ETVs respectively (table 1.). The shunt and ETV population both had a 2.3 
year mean of follow up time (table 1.). 
Table 1. Descriptive statistics for patient age at primary surgery and follow up time of 
included patients. Patients either treated with ventriculoperitoneal shunt (VPS), 
ventriculoatrial shunt (VAS) or endoscopic third ventriculostomy (ETV). 
 
Patient age at primary 
surgery (years) 
Follow up time 
(years) 
 
Shunts 
(VPS+VAS) ETVs 
Shunts 
(VPS+VAS) ETVs 
Minimum 0 0.1 1.1 1.1 
1st quartile 0.3 1 1.5 1.7 
Mean 1.7 7.1 2.3 2.3 
Median 0.4 6.9 2.3 2.2 
3rd quartile 1.6 13.2 3.3 3.0 
Maximum 11.1 16.2 3.9 3.8 
The most common etiology of hydrocephalus was IVH for shunts (30%) and Tumor for ETVs 
(67%). The category “Other” included perinatal infection with fever (n=2), pseudotumor 
cerebri (n=1), myotonic dystrophy (n=1), septo-optic dysplasia (n=1), trisomy 9 (n=1), 
congenital (n=1), membrane formation in the posterior cranial fossa (n=1), unknown (n=1). 
The full distribution of hydrocephalus etiologies is shown in figure 1, together with 
shunt/ETV frequency. 
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Figure 1. Bar graph showing frequency of hydrocephalus etiologies and treatments. 
Treatments including shunts and endoscopic third ventriculostomy (ETV). Hydrocephalus 
etiologies including aqueductal stenosis (AS), CNS infection, cyst, intraventricular 
hemorrhage (IVH), malformation, myelomeningocele (MMC), other, tumor. 
7 deaths occurred during the study where 5 of the deceased patients had hydrocephalus caused 
by tumor. Of the 59 primary surgeries, 9 (15%) had a concomitant procedure, including 
biopsy, ventriculoscopy, fenestration of cyst, neuroendoscopic septostomy, coagulation of 
choroid plexus, patching of CSF leakage from previous operation wound, or a combination of 
the above. Of the 47 shunt valves, Strata accounted for 96%, i.e. 45 in absolute numbers, 
whereas 2 Delta and no Codman were used. 2 (4%) shunts were antibiotic-impregnated. 
Seventy-five percent of the ETV procedures took place in the department of neurosurgery and 
25% in the department of pediatric surgery. Of the shunt surgeries 15% were performed in the 
neurosurgery dept. and 85% in the dept. of pediatric surgery. 
The distribution of failure of treatment for shunts and ETVs is shown in figure 2. 
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Figure 2. Distribution of treatments and subsequent types of failure with frequency shown in 
absolute numbers. Hydrocephalic patients treated with either shunt or endoscopic third 
ventriculostomy (ETV). 
Of the 47 shunts, 15 (32%) were affected of complications graded as minor and 2 (4%) as 
medium. In the 12 ETVs, 4 (33%) complications were minor and 1 (8%) was serious. The 
location of the obstruction of shunts, causing failure due to mechanical dysfunction was 
distributed as follows: ventricle catheter (n=8), shunt valve (n=1), distal catheter (n=1), 
unknown (n=3). 
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The survival of shunts and ETVs is visualized in the Kaplan-Meier analysis, in figure 3. The 
corresponding analysis from our previous study of 2010 is found in figure 4. 
 
Figure 3. Kaplan-Meier survival analysis of treatments, including shunt and endoscopic third 
ventriculostomy (ETV). 
 
Figure 4. Kaplan-Meier survival analysis of treatments, including ventriculoperitoneal shunt 
(VPS) and endoscopic third ventriculostomy (ETV). Data from our previous study of 2010 
[5]. Figure reprinted with permission from S. Karger AG, Basel. 
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Comparison to pre-protocol study of 2010 
Comparisons were made to our team’s previous study covering surgeries in 2001-2005. The 
rates of total failure of treatment, failure due to infection and failure due to mechanical 
dysfunction/insufficient function are visualized in figure 5, 6, 7. 
 
Figure 5. Rate of total failure of treatment. Treatments including ventriculoperitoneal shunt 
(VPS), ventriculoatrial shunt (VAS) and endoscopic third ventriculostomy (ETV). 
 
Figure 6. Rate of failure due to infection. Treatments including ventriculoperitoneal shunt 
(VPS), ventriculoatrial shunt (VAS) and endoscopic third ventriculostomy (ETV).  
 
Figure 7. Rate of failure due to mechanical dysfunction (shunts) or insufficient function 
(ETVs). Treatments including ventriculoperitoneal shunt (VPS), ventriculoatrial shunt (VAS) 
and endoscopic third ventriculostomy (ETV). 
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Shunts 2001-2005 vs. shunts 2012-2016 
Total failure decreased significantly from 58% to 36% (p=0.019). Both failure due to 
infection and failure due to mechanical dysfunction decreased, although not significantly, 
(p=0.180 and p=0.140 respectively). Several data variables were significantly different 
between the groups. The patients of the 2010 study were of lower age at primary surgery 
(p=0.000), had longer follow up time (p=0.000) and were different in shunt valves used 
(p=0.000). Comparisons are shown in table 2. 
Table 2. – Comparisons of failure rate and other data variables for patients treated with 
shunts. Shunted patients of this study were compared to the shunted patients of our previous 
study [5]. Abbreviations; IVH: intraventricular hemorrhage, MMC: myelomeningocele, VAS: 
ventriculoatrial shunt, VPS: ventriculoperitoneal shunt. 
 Study 2001-2005 Study 2012-2016 P-value 
Failure 58% 36% 0.019 
Patient age at primary surgery (years) 
Mean 0.9 
Median 0.1 
Mean 1.7 
Median 0.4 0.000 
Follow up time (years) 
Mean 4.9 
Median 4.8 
Mean 2.3 
Median 2.3 0.000 
Type of shunt valve  
(Codman, Delta, Strata) 
3% Codman 
42% Delta 
55% Strata 
0% Codman 
4% Delta 
96% Strata 0.000 
Failure due to infection 17% 9% 0.180 
Failure due to mechanical dysfunction 41% 28% 0.140 
Treatment distribution (VPS:VAS) 76:0 44:3 0.054 
Gender (female:male) 32:44 18:29 0.676 
Etiology hydrocephalus  
(3 most prevalent) 
26% IVH 
25% MMC 
13% Malformation 
13% Other 
30% IVH 
23% Tumor 
18% Other 0.090 
Duration of primary surgery (hours) 
Mean 1.0 
Median 0.7 
Mean 0.9 
Median 0.7 0.651 
Premature 43% 38% 0.575 
Concomitant procedure 18% 9% 0.131 
Emergency procedure 16% 11% 0.447 
Time of day of surgery  
(morning, afternoon, evening, night) 
25% morning 
64% afternoon 
8% evening 
19% morning 
60% afternoon 
17% evening 0.412 
CSF leakage 11% 6% 0.529 
Infection following CSF leakage 38% 33% 1.000 
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Shunt failure due to mechanical dysfunction per mean time of follow up equaled 11.9% 
compared to 8.4% of the 2010 study. 
To further enhance comparability between the studies, VASs were excluded from this study’s 
population of shunts to only include VPSs. This since the study of 2010 did not contain any 
VASs. Comparison of VPSs proved the same statistically significant differences as for the 
total shunts, although the p-values were slightly different.  
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ETVs 2001-2005 vs. ETVs 2012-2016 
In ETVs there was no significant difference in total failure (p=0.473), failure due to 
insufficient function (p=0.097) or failure due to infection (p=0.118). There was a significant 
difference in the two following factors: Follow up time (p=0.000) where the earlier study had 
a longer follow up time, and in the rate of patients with CSF leakage (p=0.013), where this 
study had a higher rate. Comparisons are shown in table 3. 
Table 3. – Comparisons of failure rate and other data variables for patients treated with 
endoscopic third ventriculostomy (ETV). ETV treated patients of this study were compared to 
the ETV treated patients of our previous study [5]. Abbreviations; AS: aqueductal stenosis, 
IVH: intraventricular hemorrhage. 
 Study 2001–2005 Study 2012-2016 P-value 
Follow up time (years) 
Mean 5.2 
Median 5.2 
Mean 2.3 
Median 2.2 0.000 
CSF leakage 9% 50% 0.013 
Failure 55% 42% 0.473 
Failure due to infection 0% 17% 0.118 
Failure due to insufficient function 55% 25% 0.097 
Gender (female:male) 12:10 6:6 0.064 
Patient age at primary surgery (years) 
Mean 4.5 
Median 2.3 
Mean 7.1 
Median 6.9 0.149 
Etiology hydrocephalus  
(3 most prevalent) 
50% Tumor  
18% AS 
14% 
Malformation 
67% Tumor 
17% AS 
8% IVH 
8% Cyst 0.867 
Duration of primary surgery (hours) 
Mean 1.4 
Median 0.7 
Mean 1.3 
Median 0.9 0.279 
Premature 9% 8% 1.000 
Concomitant procedure 27% 42% 0.459 
Emergency procedure 14% 8% 1.000 
Time of day of surgery  
(morning, afternoon, evening, night) 
27% morning 
55% afternoon 
14% evening 
25% morning 
67% afternoon 
0% evening 0.714 
Infection following CSF leakage 0% 33% 1.000 
ETV failure due to insufficient function per mean time of follow up equaled 11.1% compared 
to 10.5% of the 2010 study.  
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Risk factor analysis - failure of treatment - shunts 
Several univariate Cox regression models for failure of treatment (either due to infection or 
mechanical dysfunction) assessed the hazard ratio (HR) of possible risk factors. For the 47 
patients with shunts, none of the tried variables proved significant risk factors (table 4.). 
Table 4. Univariate Cox regression analyses of failure of treatment in shunts. I.e. different 
data variables were separately investigated to assess their correlation to failure of treatment in 
shunted patients. 
 Hazard Ratio (95% CI) P-value 
CSF leakage (0=no, 1=yes) 0.95 (0.13-7.25) 0.962 
Gender (0=men, 1=female) 0.46 (0.15-1.43) 0.181 
Premature (0=no, 1=yes) 1.00 (0.39-2.72) 0.950 
Emergency procedure (0=no, 1=yes) 0.56 (0.07-4.16) 0.562 
Duration of primary surgery (hours) 0.48 (0.14-1.63) 0.240 
Time of day of surgery (0=morning, 1=not morning) 1.27 (0.36-4.42) 0.709 
Concomitant procedure (0=no, 1=yes) 0.62 (0.08-4.64) 0.673 
Location of primary surgery (0=dept. of 
neurosurgery, 1=dept. of pediatric surgery) 
1.53 (0.35-6.71) 0.571 
Type of shunt valve (0=Strata, 1=Delta) 1.40 (0.18-10.66) 0.746 
 
Risk factor analysis - failure of treatment due to infection - shunts 
Of the 47 patients with shunts, 3 experienced leakage of CSF following the primary surgery. 
Out of those 3 patients, 1 later experienced failure due to infection. Using a univariate Cox 
regression model for failure due to infection, the hazard ratio (HR) of CSF leakage was 
assessed for patients with shunts. HR amounted to 6.25 (p-value 0.114 and 95% CI=0.65-
60.40). 
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Discussion 
In this study, we looked at the effects of implementing a protocol for shunt and ETV surgery. 
It was expected to show a decrease in failure of treatment due to infection, which we observed 
in shunts from 17% to 9%, however the difference was not significant. The shunt population 
was also analyzed to identify risk factors for failure of treatment and failure of treatment due 
to infection. Results proved no significant risk factors for neither. 
Shunts 
Studies have shown that 42-54% of children with VPSs require new surgery due to failure of 
treatment [8-10]. There are, to our knowledge, no studies reporting the corresponding figure 
for VASs in children. When failure rates in children were researched in our facilities for the 
years 2001 to 2005, total VPS failure was found to be 58% [5]. By using Chi square test the 
total failure rate of this study, 36%, was compared to that of the previous one and proved a 
statistically significant decrease. Although when separately considering the causes of failure, 
i.e. infection and mechanical dysfunction, both decreased but not significantly. 
Failure due to infection in shunts was reported to be 17% in our team’s study from 2010, 
which is in the high range of the 4-17% stated by the literature [11]. Several studies have 
shown significant decrease of infection rates after implementing a shunt protocol. Sarmey et 
al. evaluated eight studies implementing shunt protocols, reporting a range of 2-12% in 
absolute risk reduction [12]. The protocol we introduced in 2012 has applied for both ETV 
and shunt surgery and was created by combining what was outlined in the studies that 
reported a successful infection decrease. Our evaluation shows that failure rate due to 
infection decreased from 17% to 9% after implementing the protocol, although the difference 
was not significant. The two compared populations of shunt patients were fairly similar in 
terms of patient and surgical data. However, the following factors were significantly different: 
follow up time, patient age at surgery and type of shunt valve. The mean follow up time was 
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2.3 years compared to 4.9 years of the previous study. Instinctively one might think a shorter 
follow up time automatically would decrease failure rate since late failure of treatment might 
not be recorded. However, there is a consensus that the great majority of shunt infections 
occur in the first few months after primary surgery, which Lee et al. recently confirmed [13]. 
Therefore, we believe our minimum follow up time of 1 year per patient (2.3 years in 
previous study) was sufficient to record infection failures, and suitable for comparison. 
Regarding patient age at time of surgery, the previous study included younger patients with a 
median of 0.1 years compared to this study’s median of 0.4. This may be due to a change in 
routines after the previous study, where hydrocephalic neonates used to undergo early shunt 
surgery but new routines recommend the use of a Rickham reservoir for CSF drainage, 
thereby delaying the shunt surgery. The difference in patient age might have affected the 
comparison of failure between the populations, since studies have reported low patient age to 
increase shunt failure [9, 10]. The type of shunt valve used in this study was predominantly 
Strata whereas the previous study included more Delta and some Codman. This difference in 
shunt valve distribution is most probably due to a shift and development in routines, where 
the Strata valve was introduced and properly researched about halfway through the time 
period of the study of 2010, increasing its frequency [14]. In addition, some patients 
previously eligible for a Delta valve now use a Rickham reservoir and later a Strata valve. To 
our knowledge there are no studies suggesting an inherent difference in risk of failure in 
different types of shunt valves. 
Although a decrease in infection was observed after protocol implementation, the lack of a 
significant decrease might attribute to many things. A bigger patient population might be 
needed, where only 47 shunts were included in this study compared to 76 in the previous. 
Using the observed decrease and a desired level of statistical power of 80%, concludes that 
each compared population would need 236 patients included to prove a statistically significant 
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difference. Also, one can argue whether the specified routines of this protocol have been the 
same as the protocols of other centers reporting a significant decrease. There might be 
differences that are not stated and expressed in the protocols of previous studies, e.g. local 
differences in surgical technique and surgery routines in general. The compliance of health 
care personnel when using the introduced protocol is also of great importance. 
Failure due to mechanical dysfunction decreased from 41% to 28% after protocol 
implementation. We believe that the shorter time of follow up might have affected the 
observed difference. While shunt infections mainly happen within a few months of surgery, 
mechanical dysfunction in shunts occurs within a much wider range, up to several years after 
primary surgery [15]. To enhance comparability between the populations we calculated the 
failure rate due to mechanical dysfunction per mean time of follow up, resulting in 8.4% prior 
to protocol implementation compared to 11.9% for this study. Therefore, we don’t believe 
that there was a real decrease in mechanical dysfunction pre-protocol to post-protocol. 
ETVs 
Studies have shown that 26-48% of ETVs require new surgery due to failure of treatment [8, 
16, 17]. Fifty-five percent of ETVs failed in our team’s study from 2010, while 42% failed in 
this study, a non-significant decrease. Failure due to insufficient function also decreased, from 
55% to 25%. However, there was a significant difference in follow up time between the two 
studies, the previous having a mean of 5.2 years compared to 2.3 years of this study. Similar 
to what discussed concerning shunt mechanical dysfunction, we believe this might have 
affected the validity of the comparison of failure rate. This due to the wide time range of 
when complications of insufficient function occur in ETVs, up to several years following 
primary surgery [18]. Failure due to insufficient function per mean time of follow up equaled 
10.5% for the previous study compared to 11.1% for this study, thereby making it less likely 
that a real decrease did occur.  
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Failure of treatment due to infection increased in this study compared to 2001-2005, from 0% 
to 17%, a non-significant difference. In absolute numbers the increase was 2 infections, from 
a previous 0 to 2 in this study. If not merely attributable to chance, it is possible that the 
significant increase of CSF leakage in this study can explain the increase of infection. This 
since studies, although in adults, have reported CSF leakage as a significant risk factor for 
shunt infection, which possibly also might apply to ETVs [19, 20]. In line with this, both ETV 
patients suffering infection had experienced previous CSF leakage. 
Risk factors 
The assessment of risk factors for failure of treatment in shunts did not prove any significant 
factors. When assessing failure of treatment due to infection, CSF leakage was not found a 
significant risk factor. These results of the risk factor analysis differ from our previous study 
of 2010 where CSF leakage, duration of surgery, prematurity and concomitant procedure all 
proved to significantly increase risk for failure in shunts. We believe this is due to a small 
population, where Long suggests a minimum sample size of 100 as a rule of thumb [21]. Risk 
factor analysis of ETVs was not carried out due to the limited number of patients. 
Strengths and Weaknesses 
This study included a relatively small number of patients and we believe further studies would 
benefit of a larger sample size, to allow for a more diverse use of statistical analysis, multiple 
regression analysis for example. In turn, this would enable for adjustment of possible 
confounders and stronger conclusions to be made. 
Unfortunately, the raw data of the 2010 study lacked information of the department where 
surgery was carried out, therefore no comparison of the populations was possible in this field. 
In addition, the data lacked information of time until occurrence of failure after primary 
surgery, preventing comparisons. 
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The decade passed between patients of this study and patients in 2001-2005 might have 
brought changes affecting failure rates, changes that don’t show in our chosen parameters of 
patient and surgery data. The routines in health care concerning hygiene might have changed, 
so might have surgical procedures and techniques. The current consensus of which patient 
characteristics that make a shunt or ETV suitable could also differ from a decade ago.  
Our facilities take care of all shunt and ETV surgeries in a large region of South Western 
Sweden. This gives strength to the data of failure rates since there is no possibility of patients 
undergoing failure of treatment in other centers in the region without our knowledge. 
Conclusions and Implications 
Implementation of a new protocol decreased failure due to infection from 17% to 9% in 
shunts, however the difference was not significant. Total failure in shunts decreased 
significantly from 57% to 37%. 
This study suggest that implementation of a shunt protocol is an effective way to reduce 
failure of treatment. 
Populärvetenskaplig sammanfattning - Ger nya rutiner färre 
komplikationer efter kirurgisk behandling av hydrocefalus hos barn? 
Hydrocefalus, även kallat vattenskalle, är ett sjukdomstillstånd som innebär förhöjt tryck inuti 
skallen. Normalt finns en viss mängd vätska, kallad likvor, som flödar kring hjärnan och där 
mängden balanseras av en jämn ström av nyproduktion och avflöde. Av olika orsaker kan 
denna balans rubbas och leda till en för stor mängd likvor i systemet, det kan bero på tumör, 
blödning, infektion, cysta, etc. Den förhöjda mängden vätska orsakar ett tryck på själva 
hjärnan samt på skallbenet vilket kan orsaka kognitiva funktionshinder och ett expanderat 
skallben. Hydrocefalus kan drabba såväl barn som vuxna, men barn är vanligast. Av nyfödda 
drabbas ungefär 0,8/1000 födslar [1]. Behandling av hydrocefalus finns i två former, där båda 
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syftar till att sänka trycket i skallen. Den ena kallas shunt och innebär att ett rör inopereras för 
att avleda vätskan till annan plats, ofta in i bukhålan eller till hjärtats förmak. Den andra 
sortens behandling kallas ventrikulocisternostomi (VCS) och innebär att man under operation 
skapar en extra öppning i vätskesystemet, ofta för att förbipassera ett hinder av något slag. 
Vilken behandling som används beror mestadels på orsaken till sjukdomen. 
Till båda behandlingarna finns en relativt stor risk för att komplikationer sker och att då 
ytterligare operation måste göras. Dessa komplikationer kan antingen bestå av infektion i 
vätskan eller operationssåret, alternativt i att behandlingen slutar hjälpa vätskans avflöde.  
År 2010 publicerades en studie från Sahlgrenska sjukhuset inriktad på komplikationer för de 
barn med hydrocefalus som behandlats mellan år 2001 och 2005. Jämfört med andra studier 
så visade denna studien på en hög andel komplikationer, speciellt i shuntar på grund av 
infektion. Andra studier har i sin tur rapporterat om en tydlig minskning av 
infektionskomplikationer i shuntar efter att dom infört särskilda rutiner kring den behandlande 
kirurgin. Därför infördes liknande rutiner på Sahlgrenska år 2012, bland annat ska 
operationspersonalen bära hjälmmössa, förebyggande antibiotika användas mer strikt och 
kirurgen använda dubbla handskar. 
Denna studie har syftat till att utvärdera nyttan av dessa rutiner, genom att mäta antalet 
komplikationer på patienter som behandlats 2012–2016 och sedan jämföra med patienterna 
från 2001–2005 i den tidigare studien. Ett annat syfte med studien var att avgöra vilka 
riskfaktorer som finns för komplikationer totalt sett, samt specifikt för infektion som 
komplikation. 
Resultatet blev att antalet infektioner hos shuntar minskade efter införandet av de nya 
rutinerna, från tidigare 17% till 9%. Denna minskning var dock inte statistiskt signifikant, 
med andra ord kan det inte uteslutas att den beror på slumpen. Riskfaktoranalysen kunde inte 
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visa på några faktorer som ökar komplikationsrisken. För att kunna dra tydligare slutsatser 
behöver fler patienter ingå i en framtida studie. 
Sammanfattningsvis antyder studien att ett införande av specifika rutiner skulle kunna vara ett 
effektivt sätt att minska komplikationer av hydrocefalusbehandling. 
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